0LI as a free ligand exists in 11 entries. Examples include: 3OXZ 4TYJ 4U0I

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC29 H27 F3 N6 O
Molecular Weight532.56
Isomeric SMILESCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1

Chemical Details

Formal Charge0
Atom Count66
Chiral Atom Count0
Chiral Atomsn/a
Bond Count70
Aromatic Bond Count22
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB08901 Different stereochemistry
DescriptionPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
  • AP 24534
  • AP24534
  • Ponatinibum
SaltsPonatinib Hydrochloride
Brand NamesIclusig
Affected OrganismHumans and other mammals
IndicationPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Mechanism of actionPonatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. This protein arises from the fused Bcr and Abl gene- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in tumour size expressing native or T315I mutant BCR-ABL have been observed in rats.
Route of administrationOral
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Azoles
  • BCRP/ABCG2 Inhibitors
  • BCRP/ABCG2 Substrates
CAS number943319-70-8

Drug Targets

NameSequence SearchPharmacological ActionActions
Fibroblast growth factor receptor 4MRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALG...unknowninhibitor
Proto-oncogene tyrosine-protein kinase SrcMGSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGP...unknowninhibitor
Platelet-derived growth factor receptor alphaMGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCF...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682